ESPR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Esperion agreed to be acquired by ARCHIMEDMay 1, 2026
- HLS Therapeutics launched NILEMDO (bempedoic acid) in Canada to reduce LDL cholesterol in patients at cardiovascular riskMar 5, 2026
- Esperion Therapeutics entered into a definitive agreement to acquire Corstasis Therapeutics, expanding its cardiovascular portfolio with Enbumyst (bumetanide nasal spray)Mar 3, 2026
- Esperion partner Otsuka launches NEXLETOL® in Japan for treatment of hypercholesterolemiaNov 21, 2025
- Esperion partner HLS Therapeutics announced approval of NILEMDO® for reduction of LDL-cholesterol in Canadians at risk of cardiovascular diseaseNov 19, 2025